Globus Medical - GMED Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GMED shares.
View GMED analyst ratings or view top-rated stocks.

9 analysts have issued twelve-month target prices for Globus Medical's stock. Their GMED share price forecasts range from $62.00 to $100.00. On average, they expect the company's stock price to reach $77.36 in the next twelve months. This suggests a possible upside of 29.9% from the stock's current price.
View analysts price targets for GMED or view top-rated stocks among Wall Street analysts.

Globus Medical's stock was trading at $72.20 at the start of the year. Since then, GMED shares have decreased by 17.5% and is now trading at $59.57.
View the best growth stocks for 2022 here.

Globus Medical saw a decrease in short interest in September. As of September 15th, there was short interest totaling 4,840,000 shares, a decrease of 7.5% from the August 31st total of 5,230,000 shares. Based on an average daily volume of 607,400 shares, the days-to-cover ratio is presently 8.0 days.
View Globus Medical's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our GMED earnings forecast.

Globus Medical, Inc. (NYSE:GMED) posted its quarterly earnings results on Thursday, November, 4th. The medical device company reported $0.50 EPS for the quarter, topping the consensus estimate of $0.45 by $0.05. The medical device company had revenue of $229.72 million for the quarter, compared to analysts' expectations of $228.28 million. Globus Medical had a trailing twelve-month return on equity of 11.81% and a net margin of 15.91%. The company's revenue for the quarter was up 6.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.49 earnings per share.

Globus Medical issued an update on its FY 2022 earnings guidance on Thursday, August, 25th. The company provided earnings per share (EPS) guidance of $2.10-$2.10 for the period, compared to the consensus earnings per share estimate of $2.09. The company issued revenue guidance of $1.02 billion-$1.02 billion, compared to the consensus revenue estimate of $1.02 billion.

47 employees have rated Globus Medical Chief Executive Officer David Demski on Glassdoor.com. David Demski has an approval rating of 61% among the company's employees. This puts David Demski in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include NVIDIA (NVDA), Shopify (SHOP), CrowdStrike (CRWD), Okta (OKTA), Trade Desk (TTD), Block (SQ), Tesla (TSLA), Teladoc Health (TDOC), Zoom Video Communications (ZM) and Mastercard (MA).

Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."

Shares of GMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GMED stock can currently be purchased for approximately $59.57.

Globus Medical (NYSE:GMED) has a market capitalization of $5.93 billion and generates $958.10 million in revenue each year. The medical device company earns $149.19 million in net income (profit) each year or $1.49 on an earnings per share basis.

The company employs 2,400 workers across the globe.

Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The official website for the company is www.globusmedical.com. The medical device company can be reached via phone at (610) 930-1800, via email at investors@globusmedical.com, or via fax at 610-930-2042.